Skip to content

The Calgary Movement Disorders Advanced Care Pilot Program

The Calgary Movement Disorders Advanced Care Pilot Program

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05599659
Acronym
ACT for PD
Enrollment
100
Registered
2022-10-31
Start date
2022-11-04
Completion date
2024-11-04
Last updated
2022-10-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's Disease and Parkinsonism

Keywords

Palliative Care

Brief summary

The goal of this clinical trial is to analyse the effect of palliative care interventions on quality of life, patient satisfaction, carepartner burden and health care utilization patterns in patients living with parkisonism and their carepartners. Participants will: * Receive multidisciplinary palliative care. * Answer questions related to the quality of life, patient satisfaction, carepartner burden and health care utilization patterns.

Interventions

BEHAVIORALPalliative care

It is a pilot model of outpatient clinical care for patients in advanced stages of PDRD that will allow earlier access to PC in this population. PC visits will be in person or by telemedicine every three months and complemented with phone calls by different team members when needed as defined by the PC team. The typical visit duration will be 2 to 2.5 hours and address nonmotor symptoms, goals of care, anticipatory guidance, difficult emotions, and carepartner support. Providers will communicate in-person or via notes during the clinic visit to increase interdisciplinary coordination and meet at the end of the day for discussion including follow-up plans. The team will consist of a neurologist, a registered nurse with palliative care experience and training, a psychology counselor, a social worker, spiritual counselor and a research assistant.

Sponsors

University of Calgary
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Intervention model description

The clinical trial is a prospective cohort study analysing the effect of palliative care interventions on quality of life, patient satisfaction, carepartner burden and health care utilization patterns in patients living with parkisonism and their carepartners. Participants will: * Receive multidisciplinary palliative care. * Answer questions related to the quality of life, patient satisfaction, carepartner burden and health care utilization patterns.

Eligibility

Sex/Gender
ALL
Age
20 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

* Participants who have a PD diagnosis or another PDRD diagnosis (multiple system atrophy, corticobasal degeneration, progressive supranuclear palsy, or Lewy body dementia) * Participants who have moderate to high PC needs based on the Palliative Care Needs Assessment Tool (PC-NAT) * Participants who are between 20 and 100 years old

Exclusion criteria

* Immediate and urgent palliative care needs. These patients will be offered appropriate services immediately * Participants who have other illnesses that could require PC e.g. metastatic cancer * Participants already receiving PC and/or hospice * Patients with a diagnosis of severe cognitive impairment (Montreal Cognitive Assessment \<10). These patients will be offered appropriate services. Care partners can participate.

Design outcomes

Primary

MeasureTime frameDescription
Changes in Quality of Life Alzheimer's Disease (QOL-AD)Every 3 months for 2 yearsThe QOL-AD is a 13-item questionnaire designed to provide both a patient and a caregiver report of the quality of life (QOL), it uses a scale of 1-4 (poor, fair, good, or excellent) to rate a variety of life domains, including the patient's physical health, mood, relationships, activities, and ability to complete tasks.
Changes in 12-Item Zarit Burden Interview (ZBI-12)Every 3 months for 2 yearsZBI-12 is validated as a screening tool for advanced illness. The ZBI-12 is rated on a 12 items scale, with the severity of burden using a range of responses from 0 to 4 points per item and a total score range of 0 to 48. Scoring 0-10 is considered as a no to mild burden; 10-20, a mild to moderate burden and \>20, a high burden. It measures changes in physical, emotional, social, and financial problems that can be experienced by family caregivers.
Changes in Health Care Utilization surveyEvery 3 months for 2 yearsWe will perform a Health Service Utilization Survey to measure changes in the number of hospitalizations, emergency room visits, home health services, and nursing home placement.

Secondary

MeasureTime frameDescription
Changes in Edmonton Symptom Assessment Scale revised for Parkinson's Disease (ESAS-PD)Every 3 months for 2 yearsThe ESAS is a comprehensive, yet brief and practical self-reporting tool of symptom severity (intensity) for nine common symptoms of advanced cancer (pain, tiredness, nausea, depression, anxiety, drowsiness, appetite, well-being, shortness of breath), with the option of adding a tenth patient-specific symptom. It rates the severity of each symptom on a 0 to 10 scale, where 0 represents the absence (or best possible intensity) of the symptom and 10 represents the worst possible severity.
Changes in the Functional Assessment of Chronic Illness Therapy-Spiritual Well-Being (FACIT- Sp-12)Every 3 months for 2 yearsThe 12-item Spiritual Well-Being Scale (FACIT-Sp-12) is the most widely used measure of spiritual well-being among those with long-term illness. The FACIT-Sp comprises 12 statements, or items, each of which is rated on a 5-point scale by the respondent based on how true the item was during the past week, 0 for not at all, 1 for a little bit, 2 for somewhat, 3 for quite a bit and 5 for very much.
Semi-structured Qualitative Interview to receive Patient and Care Partner recommendationsEvery 3 months for 2 yearsIt will be performed on patients and care partners for optimizing the palliative care services provided and delivery methods.

Countries

Canada

Contacts

Primary ContactVeronica Bruno, MD, MPH
veronica.bruno@ucalgary.ca4039194262
Backup ContactKarla Cantu Flores, MD
karla.cantuflores1@ucalgary.ca4032107542

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026